glp-1 risks and side effects nausea: How to handle GLP-1s' most common effect GLP-1 and Low Blood Pressure:

Phase III results for retatrutide are set to be released later in 2025 and in early 2026, but an earlier phase II trial recorded between a 7.2% and 17.5% reduction in body weight after 24 weeks, depending on the dose (7.2% on 1mg, 17.5% on 12mg), and up to a 24.2% reduction in body weight after 48 weeks for those on 12mg (-8.7% change for those on 1mg) 8

In one study, 88% of diabetic patients with nausea and vomiting reported benefits with TCAs

10.1016/j.ejphar.2016.06.016

The primary mechanism of action involves mimicking the naturally occurring hormone GLP-1, which is released from the intestines following food intake

GO DEEPER WITH DR